
Luis Lara-MejÃ-a

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1485925/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. Lung Cancer, 2021, 152, 119-126.	2.0	17
2	Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 510-522.	2.6	5
3	Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells. Pathology and Oncology Research, 2021, 27, 597499.	1.9	2
4	Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. Lung Cancer, 2021, 155, 183-190.	2.0	8
5	RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. BMC Cancer, 2021, 21, 892.	2.6	3
6	Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs. Cancer Biomarkers, 2021, 32, 1-13.	1.7	2
7	Clinical Impact of the COVID â€19 Pandemic in Mexican Patients with Thoracic Malignancies. Oncologist, 2021, 26, 1035-1043.	3.7	6
8	Brigatinib in <i>ALK</i> -positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP). Future Oncology, 2021, 17, 169-181.	2.4	5
9	Locoregional control and toxicity after pleurectomy/decortication and <scp>intensityâ€modulated</scp> pleural radiation therapy in patients with malignant pleural mesothelioma. Thoracic Cancer, 2020, 11, 3448-3455.	1.9	1
10	Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVIDâ€19 pandemic: the THOCOoP cooperative group. Critical Reviews in Oncology/Hematology, 2020, 153, 103033.	4.4	17
11	Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations. BMC Cancer, 2020, 20, 829.	2.6	11
12	Carboplatin plus etoposide or topotecan for small-cell lung cancer. Lancet Oncology, The, 2020, 21, 1132-1134.	10.7	4